The Department of Health is aware of an ongoing issue with intermittent supply constraints of EpiPen® 0.3mg and EpiPen® Jr 0.15mg Adrenaline Auto-Injectors due to manufacturing delays.
It is unable to make any specific treatment recommendation to individual patients but would advise that there are two alternative adrenaline auto-injector products available in the UK. Patients who are concerned about the current supply constraints of EpiPens® should speak to their GP practice regarding the possibility of alternative treatments.
The Health and Social Care Board (HSCB) is actively monitoring the availability of all Adrenaline Auto-Injectors in conjunction with wholesalers, and has issued advice to prescribers and community pharmacies in Northern Ireland.
Departmental officials are in contact with colleagues in the Department of Health and Social Care (London) (DHSC) who are in regular dialogue with the supplier of EpiPen®. The DHSC has advised that they will be
working closely with all manufacturers of adrenaline auto-injectors, the Medicines and Healthcare products Regulatory Agency, Anaphylaxis UK and other stakeholders to seek to address the supply constraints as appropriate.
Patients are also advised to retain their current EpiPens® until a new supply can be obtained.
Notes to editors:
- For media enquiries please contact the DoH Press Office team on 028 9052 0575 or email firstname.lastname@example.org For out-of-hours please contact the Duty Press Officer on 028 9037 8110 and your call will be returned. Follow us on twitter @healthdpt
- Extension to term of Office of a Non-Executive Member of the Patient and Client Council 17 July 2019
- Reappointment of two Non-Executive Directors to the Public Health Agency 09 July 2019
- Complaints and Compliments received by HSC Trusts in Northern Ireland 2018-19 04 July 2019
- Transformation fund continues to support much-needed change 04 July 2019